Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV

New VESALIUS-CV data show broad cardiovascular benefits of evolocumab in high-risk primary prevention patients with diabetes and no atherosclerosis.